Indian Stock Market Performance After Close: Sensex Falls 372 Points, Nifty Ends Below 24,000 on 29 June 2026
Indian markets finished lower on 29 June 2026, with the Sensex losing 372.10 points to close at 76,728.37 and the Nifty 50 slipping 109.75 points to end at 23,946.25. The session was cautious, with weakness in banks, autos, and select large-cap names outweighing gains in a few defensive and pharma-linked stocks.blog.liquide+1
Market overview
The June 29 session saw broad pressure across benchmark indices as investors turned risk-averse after recent volatility. The Nifty Bank also declined, reflecting softness in financial stocks and added pressure on the broader market tone.blog.liquide
Market sentiment was shaped by mixed sector participation, with buying interest appearing in pharma and select metals, while capital-intensive and consumer-discretionary names faced selling. The move below 24,000 on the Nifty also signaled that traders were cautious about chasing the market higher after the previous rebound.breakingtrade+1
The overall backdrop suggested a consolidation phase rather than a strong directional trend, as investors balanced earnings expectations, crude oil movement, and global headlines. That made intraday rebounds harder to sustain and kept closing levels under pressure.hdfcsky+1
Sector action
Pharma stocks were among the few bright spots, helped by defensive buying and stock-specific strength. Metals also showed resilience in parts of the session, while infrastructure and energy names were more uneven.breakingtrade
On the losing side, banks and autos dragged more heavily, with Kotak Mahindra Bank, Eicher Motors, and Mahindra & Mahindra among the names that weakened. The pressure in these sectors contributed to the broader decline in benchmark indices.hdfcsky+1
Top 5 gainers
- Cipla: +2.64%hdfcsky
- Max Healthcare Institute: +2.37%upstox
- Dr. Reddy’s Laboratories: +2.26%upstox
- Coal India: +1.72%upstox
- Eternal: +1.57%upstox
Pharma led the gainers list, showing defensive support in an otherwise weak market. Coal India and Eternal also posted respectable gains, helping limit the extent of the decline in the broader index.hdfcsky+1
Top 5 losers
- Kotak Mahindra Bank: -2.93%upstox
- Eicher Motors: -2.70%hdfcsky
- Mahindra & Mahindra: -2.43%upstox
- Adani Enterprises: -2.24%upstox
- Tata Motors PV: -2.10%upstox
The losers were led by financials and autos, two important areas of the market that often influence benchmark direction. Adani Enterprises also came under pressure, adding to the weakness in large-cap sentiment
========================================================
Markets at Close
29th June, 2026
Nifty below 24,000, Sensex down 372 pts; auto, banks drag, metal, pharma gain
Biggest Nifty losers were Kotak Mahindra Bank, M&M, Tata Motors Passenger Vehicles, Adani Enterprises, Interglobe Aviation, while gainers included Max Healthcare, Coal India, Dr Reddy’s Laboratories, Eternal and Trent. Among sectors, Auto index shed 2%, while PSU Bank, Media, IT, Oil & Gas down 1-1.5%. On the other hand, Metal, Pharma, Healthcare up 1% each. The Nifty midcap index slipped 0.2 percent and smallcap index fell 0.6 percent.
Rupee at Close
29th June, 2026
Indian rupee erased all the intraday gains and ended at day’s low 94.53 per dollar on Monday against Thursday’s close of 94.40.
Source : moneycontrol
You may be interested in this article – Nifty Option Chain Analysis Guide
FII’s & DII’s Activity on 29th June, 2026
Net value in crores
| BUY | SELL | |
| DII | 2,801.45 | |
| FII | 1,350.10 |
Source : NSE
You may be interested in this article – How to trade with Support and Resistance
Factors driving defensive buying in pharma stocks today
Defensive buying in pharma stocks today appears to be driven by a rotation into safer earnings profiles after broader market weakness, with investors preferring companies that tend to hold up better in volatile sessions. Pharma also benefited from stock-specific strength in names like Cipla, Max Healthcare, and Dr. Reddy’s, which helped lift the Nifty Pharma pack on a day when the broader market was under pressure.hdfcsky+1
Why pharma attracted buyers
One major reason is the classic defensive trade: when investors are cautious, they often move toward sectors with steadier demand and relatively predictable cash flows. Pharma fits that profile because healthcare spending is less cyclical than autos, metals, or discretionary consumption.economictimes.indiatimes
A second factor is sector rotation. Recent market action showed weakness in banks, autos, and other cyclical pockets, so funds naturally shifted toward defensives, including pharma, to reduce portfolio volatility. That kind of rotation is especially visible when the market is consolidating or reacting to global uncertainty.upstox+2
Earnings visibility also matters. The sector often draws interest when investors expect stable quarterly performance, and company-specific updates or margin resilience can make the segment more attractive than higher-beta names.upstox
Stock-specific support
On June 29, pharma strength was not just thematic; it was also stock-led. Cipla, Max Healthcare, and Dr. Reddy’s were among the gainers, showing that investors were willing to pay for quality names with stronger defensive characteristics.hdfcsky+1
This matters because market participants usually prefer large, liquid pharma names when they want safety. These stocks are easier to trade, have broader analyst coverage, and often act as parking places for capital during uncertain sessions.economictimes.indiatimes+1
Broader market backdrop
The broader market closed lower, with the Sensex and Nifty both ending in the red, which reinforced the appeal of defensives. When benchmarks weaken and risk appetite fades, pharma can outperform simply because it offers relative stability compared with more cyclical sectors.blog.liquide+1
Rising crude prices, global tensions, and uneven sector participation also helped keep sentiment cautious. In that environment, investors often favor sectors that are less sensitive to macro shocks, and pharma is a common first choice.breakingtrade+1
What it means now
If defensive buying continues, pharma could stay supported even without a full market rally. However, sustained upside will still depend on earnings delivery, margin trends, and whether the broader market stabilizes enough for flows to expand beyond defensives.upstox
For today, the takeaway is simple: pharma bought because the market wanted safety, visibility, and relative strength. That combination is usually enough to attract steady inflows when the rest of the market looks uncertain.
*Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
NOTE: *** The above information is based on the source and just for information and educational purposes only. Please consult your financial advisor before buying any stocks. Thank You ***
Important Links which may interest you :